55 results about "Invasion and migration" patented technology

The invention discloses poplar and phellinus igniarius polysaccharide SVP-1 as well as a preparation method and application thereof, and belongs to the field of biological medicines. The poplar phellinus igniarius polysaccharide SVP-1 provided by the invention has remarkable anti-tumor activity, and can effectively inhibit proliferation, invasion and migration of tumor cells so as to block malignant progression of tumors. The structure is clear, the preparation method is controllable, the stability and biological activity of polysaccharide components are ensured, and a reliable basis is provided for development of antitumor drugs. When the traditional Chinese medicine composition is used together with radiotherapy and chemotherapy medicines, a synergistic effect can be achieved, the sensitivity of tumors to treatment can be improved, the toxic and side effects of radiotherapy and chemotherapy can be relieved, and the effects of reducing toxicity and increasing efficiency are achieved. According to the combined treatment strategy, the curative effect of the existing tumor therapy can be remarkably improved, meanwhile, adverse reactions are reduced, and a new optimization scheme is provided for clinical tumor treatment.

The invention provides a bacterial outer membrane vesicle presenting Stoppin peptide as well as a construction method and application of the bacterial outer membrane vesicle, and relates to the technical field of biological medicines. According to the invention, a fusion protein ClyA-Stoppin is firstly designed and synthesized, and the fusion protein ClyA-Stoppin is displayed on the surface of the bacterial outer membrane vesicle by using a genetic engineering technology, so that the engineered bacterial outer membrane vesicle W-Stoppin OMV for targeting presentation of Stoppin peptide is successfully constructed. The W-Stoppin OMV provided by the invention has a remarkable inhibition effect on invasion and migration of tumor cells and can be used for remarkably promoting apoptosis of the tumor cells. According to the present invention, with the Stoppin monopeptide, the problems of insufficient Stoppin cell penetrability and difficult intracellular delivery are effectively solved, compared with the Stoppin monopeptide, the Stoppin monopeptide shows the excellent anti-tumor effect, and the migration inhibition, the invasion inhibition and the apoptosis promotion effects on the tumor cells are significantly increased. The W-Stoppin OMV provided by the invention has huge application potential in the aspect of preparation of anti-tumor drugs.

The application specifically relates to a breast cancer invasion and metastasis model based on anisotropic collagen hydrogel and a construction method thereof, and belongs to the technical field of biomedical materials and tumor microenvironment. The anisotropic hydrogel with highly parallel arrangement of collagen fibers is prepared by adopting a PDMS mold pre-tensioning-stress rebound process, and the orientation index is 0.62+ / -0.05. The hydrogel has high matching of mechanical properties with the breast cancer microenvironment in vivo and good biocompatibility. The model can induce mature adipocytes to dedifferentiate and fibroblasts to transdifferentiate, and drive the breast cancer cells to have enhanced invasion and migration ability and EMT phenotype, and reproduce a pathological axis of "collagen orientation→adipocyte dedifferentiation→breast cancer invasion and metastasis". The process depends on the activation of a DDR1-integrin beta1-FAK-YAP signal path, and a DDR1 inhibitor can effectively reverse the above effects. The application can be used for breast cancer metastasis mechanism research and drug screening targeting the DDR1 path.

The invention relates to application of (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium in preparation of anti-cancer drugs, and belongs to the technical field of medical application, the structure of (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium is as shown in the following formula I, the (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium can inhibit the growth of gastric cancer cells, inhibit the proliferation, invasion and migration of the gastric cancer cells by promoting the autophagy and mitochondrial rupture of AGS and HGC-27 cells of the gastric cancer cells, and block the gastric cancer cells in the G1 stage. Furthermore, in-vivo experiments of mice prove that ZWK-3 can inhibit tumor growth of the mice, shows obvious dose dependence, and does not influence the body weight and visceral indexes of the mice at the same time. Formula I.

The application discloses application of Rhamnus hemisphaerica in preparation of anti-pancreatic cancer drugs, wherein the Rhamnus hemisphaerica is dry root of Semiliquidam bar cathayensis Chang of Rhamnaceae. Researches show that the Rhamnus hemisphaerica can inhibit proliferation, invasion and migration of pancreatic cancer cells Pan-1, promote apoptosis, has anti-pancreatic cancer activity, can significantly inhibit growth of tumor of a subcutaneous nude mouse xenograft model of pancreatic cancer cells Panc-1, significantly inhibit expression of a tumor proliferation related factor Ki67, and has no obvious toxic side effect on mice. The application firstly discloses that the Rhamnus hemisphaerica has obvious anti-pancreatic cancer activity, can be used for preparation of anti-pancreatic cancer drugs, provides a new efficient and safe drug source for treatment of pancreatic cancer, and provides a basis for further development and utilization of the Rhamnus hemisphaerica.

The application belongs to the field of medicine, and particularly relates to application of CZC-54252 in preparation of a drug for treating esophageal squamous cell carcinoma. The results of the application show that CZC-54252 can efficiently inhibit expression of RSK4 enzyme, and can efficiently inhibit proliferation, invasion and migration of esophageal squamous cell carcinoma cells. In combination with Afatinib, the proliferation of an esophageal squamous cell carcinoma erlotinib-resistant strain can be significantly inhibited, and the results provide an effective technical means for treatment and prognosis of esophageal squamous cell carcinoma patients.

The present invention discloses a tumor-activated sorafenib prodrug, its preparation method, and its application, belonging to the field of biomedicine technology. The present invention designs a tumor-activated sorafenib prodrug, composed of sorafenib and ferrocenecarboxylic acid molecules as its main structure. It can specifically activate cytotoxicity at the tumor site, and compared to sorafenib, it is more effective in killing liver cancer cells. Furthermore, it undergoes an in situ Fenton reaction, generating oxygen to alleviate tumor hypoxia and reduce tumor invasion and migration. The Fenton reaction can generate highly toxic hydroxyl radicals, which kill liver cancer cells and provide auxiliary treatment.

The invention belongs to the technical field of biological medicine, and particularly relates to application of coniferyl aldehyde in preparation of anti-cancer drugs. The invention discloses application of coniferyl aldehyde in preparation of anti-cancer drugs, coniferyl aldehyde can significantly inhibit invasion and migration ability of hepatocellular carcinoma cells, cancer cells cannot break through primary parts through key links such as interference of movement and adhesion of the cancer cells and degradation of extracellular matrixes, invasion of tumors to surrounding tissues is reduced, and the anti-cancer effect is improved. The occurrence rate of remote metastasis is reduced, the non-metastasis lifetime of the patient is prolonged, and more treatment time and survival opportunities are won for the patient; a large number of cell experiments and animal experiments prove that the medicine has no obvious liver and kidney toxicity under the treatment dosage, the tolerance of a patient to treatment is improved, the smooth proceeding of the treatment process is guaranteed, and the living quality of the patient is effectively improved.

The present invention discloses the use of the Prosaposin gene / protein, belonging to the technical field of cancer precision medicine drugs. Through experiments such as ELISA and multi-color immunofluorescence, the present invention has confirmed that the Prosaposin protein is expressed in the blood and cancer tissues of gastric cancer patients, significantly higher than its expression in the blood of healthy people and benign gastric mucosa tissues, and the prognosis of patients with high expression of the Prosaposin protein is poor. The Prosaposin gene / protein is a target for precision therapy, and a targeted drug for treating diseases with high expression of the Prosaposin gene / protein such as gastric cancer, and a kit for diagnosis or prognosis judgment are prepared. The CRISPR-Cas9 system of the present invention can efficiently knock out the Prosaposin gene overexpressed in gastric cancer, inhibit the proliferation, invasion and migration of gastric cancer cells, and the system is simple to operate and has a high knockout efficiency. Therefore, the present invention has good application prospects.

The invention discloses application of a lipid synthesis inhibitor in treatment of breast cancer. Researches prove that F.n colonization exists in breast cancer tissues, and the F.n can regulate and control lipid deposition related gene expression and lipid metabolism change of tumor-related macrophages, so that lipid deposition of the macrophages and proliferation, invasion and migration capabilities of tumor cells are promoted; after the lipid deposition inhibitor is added, the lipid metabolism disorder of the tumor-associated macrophages can be inhibited, the tumor malignant phenotype is finally inhibited, and the treatment of the breast cancer is realized. The invention provides a new potential therapeutic target and a new therapeutic drug for effective treatment of breast cancer.

The application discloses poplar phellinus polysaccharide SVP-1, a preparation method and application thereof, and belongs to the field of biological medicines. The poplar phellinus polysaccharide SVP-1 provided by the application has significant antitumor activity, can effectively inhibit the proliferation, invasion and migration of tumor cells, and thus blocks the malignant progression of tumors. The structure is clear, the preparation method is controllable, the stability and biological activity of the polysaccharide component are ensured, and a reliable foundation is provided for the development of antitumor drugs. The combination with radiotherapy and chemotherapy drugs can play a synergistic effect, can not only improve the sensitivity of tumors to treatment, but also reduce the toxic and side effects of radiotherapy and chemotherapy, and realizes the effect of 'attenuation and synergism'. The combined treatment strategy can significantly improve the curative effect of the existing tumor therapy, while reducing the adverse reactions, and provides a new optimization scheme for clinical tumor treatment.

The invention provides a novel human distal bile duct cancer cell line with TP53 missense mutation and application, the novel human distal bile duct cancer cell line CBC3T-3 is established, the cell line is preserved in the China Center for Type Culture Collection (the preservation number is CCTCC NO: C202555), the uniqueness and stability of the cell line are proved through STR typing and karyotype analysis, and the TP53 missense mutation novel human distal bile duct cancer cell line has the advantages that the TP53 missense mutation novel human distal bile duct cancer cell line CBC3T-3 can be used for preparing the TP53 missense mutation novel human distal bile duct cancer cell line CBC3T-3; and a plurality of driver gene mutations including TP53 missense mutation are carried. The CBC3T-3 has strong proliferation, invasion and migration capabilities, has high tumor formation rate in immunodeficient mice, is resistant to cis-platinum and sensitive to paclitaxel and gemcitabine, and provides an experimental basis for selection of clinical chemotherapy regimens. According to the model, the TP53 missense mutation type distal bile duct cancer in-vitro model is successfully established, and a key experimental platform is provided for deeply researching the drug resistance mechanism of the TP53 missense mutation type distal bile duct cancer and developing an individualized treatment strategy aiming at the subtype of the TP53 missense mutation type distal bile duct cancer.

This invention discloses 1-(1H-imidazol-2-yl)-β-carbamoline-3-formyl-Arg-Gly-Asp-Val, its preparation method, its activity in inhibiting tumor cell invasion and migration, and its activity in inhibiting tumor metastasis to the lungs in Lewis mice. Therefore, this invention discloses its application in the preparation of drugs for treating cancer metastasis.

The present invention belongs to the technical field of anti-tumor drug research, and specifically relates to a splicing factor WBP11 and uses of its inhibitors, and drugs for preventing or treating colorectal cancer. WBP11 Significantly inhibited the proliferation, invasion and migration of colorectal cancer cells, and WBP11 The expression level in colorectal cancer tissues is higher than that in corresponding normal tissues. WBP11 High expression of TNF-α leads to poor prognosis of colorectal cancer. WBP11 It has been confirmed that both siRNA and Cas knockdown plasmids have good effects in inhibiting tumor development and are expected to be used in the development of anti-colorectal cancer drugs.

The invention discloses an application of sodium polystyrenesulfonate (PSS) in preparation of a medicine for treating hepatocellular carcinoma. According to the application, the PSS is used as an effective component for treating the hepatocellular carcinoma. The invention also provides a medicine for treating hepatocellular carcinoma, and the effective component of the medicine comprises sodium polystyrenesulfonate. PSS can effectively inhibit invasion and migration of liver cancer cells in vitro, reduce the relative content of potassium ions in an HCC cell line and depolarize cell membranes, and obviously inhibit development of liver cancer. Meanwhile, PSS has the advantages of being high in safety, few in side effect, wide in source and easy to synthesize. Therefore, PSS can effectively treat the hepatocellular carcinoma and can effectively prevent metastasis of the hepatocellular carcinoma, so that the hepatocellular carcinoma is prevented from developing from the early stage to the middle and advanced stage, and the PSS has great application prospects in preparation of the medicine for treating the hepatocellular carcinoma.

The application discloses application of panax notoginseng saponin R1 in diagnosis and treatment of ovarian cancer and belongs to the field of medical biology.The first object of the application is to disclose application of a natural traditional Chinese medicine component in preparation of a medicine for treating ovarian cancer, and the panax notoginseng saponin R1 belongs to the technical field of new purposes of medicines.The application finds that the panax notoginseng saponin R1 has a significant inhibitory effect on the growth of human ovarian cancer cell strains A2780 and SK-OV-3 through in-vitro anti-tumor activity evaluation, and simultaneously significantly induces cell apoptosis.In addition, the other object also provides a molecular action mechanism and a target point of the panax notoginseng saponin R1 for inhibiting ribosome synthesis; the in-vitro anti-tumor evaluation finds that the natural compound panax notoginseng saponin R1 significantly inhibits proliferation, invasion and migration of ovarian cancer cells and promotes apoptosis of the ovarian cancer cells, and experiments prove that the panax notoginseng saponin R1 inhibits ribosome synthesis by inhibiting activation of an mTOR-RPS6 signal path, and then plays an anti-tumor role.

The application discloses application of a traditional Chinese medicine gecko microRNA in preparation of an anti-tumor metastasis treatment drug. Through extensive and in-depth research, the application discloses that the gecko-miR-2862 mimic can inhibit invasion and migration of liver cancer cells through a scratch test and a Transwell test; the gecko-miR-2862 mimic is transfected into cancer cells to first disclose that the gecko-miR-2862 mimic can target and inhibit mRNA of a cancer gene SRC in the cancer cells and protein expression of genes related to the SRC signal path, and further discloses the treatment effect of the gecko-miR-2862 mimic on tumor metastasis. The application provides a direction and a technical basis for research and development of a new drug for resisting tumor metastasis treatment, and further develops a new traditional Chinese medicine gecko microRNA as an anti-tumor metastasis treatment drug.

The present invention discloses the application of the APMAP gene and its RNAi lentiviral interference system, which relates to the field of biomedical technology. The APMAP gene and the RNAi lentiviral interference system of the APMAP gene of the present invention are prepared for the treatment of colorectal cancer. This RNAi lentiviral interference system can efficiently knockdown the APMAP gene / protein in colorectal cancer cells, inhibit the proliferation, invasion and migration of cancer cells, with simple operation and high efficiency. The present invention also discloses using the APMAP gene / protein as a target for precision therapy to prepare a kit for the diagnosis or prognosis judgment of diseases with high expression of the APMAP gene / protein such as colorectal cancer, and it is also used to prepare targeted drugs.

The application discloses application of a PI3K-gamma-delta signal path inhibitor in preparation of a product for treating central nervous system leukemia and the product, and solves the technical problem that the prior art lacks a molecular targeting product for acute lymphoblastic leukemia with CNSL which has better effect. The application comprises: application of the PI3K-gamma-delta signal path inhibitor in preparation of a product for treating acute lymphoblastic leukemia with central nervous system leukemia, and application of the PI3K-gamma-delta signal path inhibitor in preparation of a product for inhibiting proliferation, invasion and migration of acute lymphoblastic leukemia with central nervous system leukemia. The application also comprises a product of the PI3K-gamma-delta signal path inhibitor. The application discloses that central nervous system leukemia is closely related to an expression level of MSLN, and the PI3K-gamma-delta signal path inhibitor can inhibit the infiltration degree of acute lymphoblastic leukemia with central nervous system leukemia by reducing the expression level of MSLN, and prolong the survival time.

The invention discloses a method for regulating and controlling tumor invasion and migration ability through a TGF-betaSmad7 signal by using MYL9 as a marker, which is characterized by comprising the following steps: (1) culturing kidney cancer cells in a DMEM (Dulbecco Modified Eagle Medium) added with 10% fetal calf serum; (2) carrying out gene silencing by using a HiPerFect transfection reagent, specifically knocking down the expression of MYL9, and regulating and controlling a TGF-beta1 / Smad7 signal channel; and (3) detecting the migration and invasion ability of the kidney cancer cells by adopting a Transwell experiment, adding 200 mu L of DMEM containing 0.5% of FBS into the upper hole, adding 600 mu L of DMEM containing 10% of FBS into the lower hole, and filling the kidney cancer cells treated in the step (2) for a migration and invasion experiment. MYL9 is connected with matrix mechanics, angiogenesis and immune escape through a TGF-beta / Smad7 signal axis, and by regulating and controlling the TGF-beta Smad7 signal, the invasion ability of kidney cancer cells can be effectively reduced, the traditional cognition of single-dimensional regulation and control on a kidney cancer microenvironment is broken through, and a multi-dimensional perspective is provided for understanding tumor progression.

The present invention relates to the technical field of anticancer drugs and provides the use of shikonin derivatives in the preparation of anti-pancreatic cancer drugs. The present invention has found that shikonin derivatives have a significant inhibitory effect on pancreatic cancer cells and have broad application prospects in the preparation of anti-pancreatic cancer drugs. The results of the embodiment show that shikonin derivatives inhibit the IC of PANC-1 cells. 50 The ion concentration of shikonin derivatives was 1.218 μM, effectively inhibiting the proliferation, invasion, and migration of PANC-1 cells and arresting the cell cycle. Shikonin derivatives significantly promoted apoptosis in PANC-1 cells in a dose-dependent manner. Animal studies demonstrated that shikonin derivatives significantly inhibited the growth of nude mouse xenograft tumors, disrupted their pathological structures, and induced apoptosis in cancer cells, without significant hepatotoxicity or renal toxicity, demonstrating an overall good safety profile. LiP-MS experiments demonstrated that PKM2 is a potential target of shikonin derivatives.

The invention belongs to the technical field of molecular biology and drug screening, and provides a method for screening phenelzine sulfate based on SOCS5-CP key binding amino acid loci and application, and the method comprises the following steps: screening out SOCS5-CP binding key amino acid loci through alanine virtual point mutation, and determining a binding pocket; performing virtual screening by taking a binding pocket as a docking region through a ligand molecule to obtain a compound with optimal binding energy; the obtained medicine is screened through AMDET; carrying out subsequent in-vitro cell experiments by using the selected compounds, and carrying out further screening; screening is carried out by combining molecular docking and virtual screening methods with in-vitro experiments, it is found that phenelzine sulfate can be stably combined to key amino acid sites of SOCS5-CP, and in-vitro experiments show that phenelzine sulfate can effectively inhibit combination of SOCS5-CP, so that the protein expression level of HIF1a in hepatoma carcinoma cells is lowered, and the activity of the HIF1a in the hepatoma carcinoma cells is improved. And the compound also has a remarkable inhibition effect on invasion and migration ability of primary liver cancer.

The invention discloses application of a substance for inhibiting polyamine synthesis in preparation of a medicine for treating or relieving endometrial cancer. According to experimental verification of an endometrial cancer cell model and an animal model, it is found that high-fat culture promotes rise of endometrial cancer cell ODC1 and accumulation of polyamine metabolites; mouse serum polyamine metabolites can be up-regulated by feeding the bilateral ovariectomy mouse with high fat; oA-induced polyamine metabolite accumulation and invasion and migration of endometrial cancer cells can be inhibited by knocking down the ODC1; in an animal model, ODC1 is knocked out, and transplantation tumor growth and lymph node metastasis promoted by high fat can also be inhibited by applying an ODC1 inhibitor DFMO. The DFMO can improve the sensitivity of endometrial cancer patients which are resistant to chemotherapeutic drugs. The invention finds that the serum polyamine can be used as a target for developing a medicine for treating or relieving endometrial cancer, and can also be used as a marker for grouping endometrial cancer patients of mammals.

The application discloses application of circular RNA Hsa_circ_0006332 in diagnosis and treatment of esophageal squamous cell carcinoma and belongs to the field of biological medicine. The application comprises application of a reagent capable of detecting Hsa_circ_0006332 or an expression amount thereof in preparation of a kit for diagnosing esophageal squamous cell carcinoma, wherein the Hsa_circ_0006332 nucleotide sequence is SEQ ID NO. 1. The application also comprises application of a component capable of inhibiting or blocking expression of Hsa_circ_0006332 in preparation of a medicine for treating esophageal squamous cell carcinoma. The application changes an expression level of Hsa_circ_0006332 in esophageal squamous cell carcinoma cells through construction of Hsa_circ_0006332 specific siRNAs and other molecular biology means, reveals that interference with Hsa_circ_000632 expression can significantly inhibit esophageal squamous cell carcinoma cell proliferation, invasion and migration, promote cancer cell apoptosis and other tumor cell biological phenotypes. Therefore, Hsa_circ_0006332 can be used as a treatment target in preparation, screening or treatment of esophageal squamous cell carcinoma or medicines for inhibiting migration and invasion of esophageal squamous cell carcinoma, and provides a new treatment method for intervention or treatment of esophageal squamous cell carcinoma.

The invention relates to the technical field of anti-cancer drugs, and provides application of an alkannin derivative in preparation of anti-pancreatic cancer drugs. Research finds that the shikonin derivative has a remarkable inhibition effect on pancreatic cancer cells and has a wide application prospect in preparation of pancreatic cancer resisting drugs. The result of the embodiment shows that the IC50 value of the shikonin derivative for inhibiting the PANC-1 cell is 1.218 mu M, the proliferation, invasion and migration capabilities of the PANC-1 cell can be effectively inhibited, and the PANC-1 cell cycle is retarded; the alkannin derivative can obviously promote PANC-1 cell apoptosis, and is dose-dependent; animal experiment results show that the shikonin derivative can significantly inhibit growth of transplanted tumors in nude mice, destroy the pathological structure of the transplanted tumors and induce apoptosis of cancer cells, and meanwhile, the shikonin derivative has no obvious liver and kidney toxicity and is good in overall safety. LiP-MS experimental results show that PKM2 is a potential action target of the alkannin derivative.

The invention discloses application of MRGPRX2 in diagnosis and treatment of esophageal cancer, and belongs to the field of biological medicine. The application comprises a reagent capable of detecting the MRPGRX2 or the expression quantity of the MRPGRX2, an application of the reagent in preparation of a kit for auxiliary diagnosis of esophageal cancer, or an application of the reagent in screening of potential drugs for treating esophageal cancer. The invention relates to a reagent capable of detecting MRPGRX2 or the expression quantity of MRPGRX2, and application of the reagent in preparation of a reagent for detecting the polarization state of mast cells. The invention relates to an application of a component for inhibiting or blocking MRPGRX2 expression in preparation of a medicine for treating esophageal cancer. The component for inhibiting or blocking the expression of MRPGRX2 is used for preparing a medicine for blocking the promotion effect of mast cells on invasion and migration of esophageal cancer cells. The expression level of MRGPRX2 in mast cells is changed through molecular biology means such as construction of MRGPRX2 specific siRNAs, and it is revealed that M2 polarization of the mast cells can be remarkably inhibited by interfering MRGPRX2 expression, and then tumor cell biological phenotypes such as invasion and migration of esophageal cancer cells are inhibited. Therefore, the MRGPRX2 can be used as a new tumor immunotherapy target to be applied to preparation and screening of drugs for detecting esophageal cancer prognostic markers or inhibiting esophageal cancer invasion and migration, and a new method is provided for prognostic evaluation or treatment of esophageal cancer.

The application provides application of indole acetic acid in intervention or treatment of thyroid cancer caused by long-term low-dose ionizing radiation, and belongs to the field of biomedical technology. It is found that indole acetic acid (IAA) is significantly negatively correlated with the occurrence of thyroid nodules after low-dose radiation, the proliferation, clone formation, invasion and migration of BCPAP cells can be inhibited after IAA is supplemented, and the tumor formation ability is greatly reduced, so the thyroid cancer caused by long-term low-dose ionizing radiation can be treated by supplementing IAA. The application also screens the KCNE4 gene for regulating the thyroid cancer caused by long-term low-dose ionizing radiation, and IAA can inhibit the expression of the gene, which indicates that IAA and the inhibitor of the gene both have the potential of serving as a therapeutic target for the thyroid cancer caused by long-term low-dose ionizing radiation.

The invention belongs to the field of biotechnology and medical technology, and particularly relates to application of a PPAR gamma agonist in preparation of a medicine for preventing, relieving or treating preeclampsia. Experiments find that placenta lipid metabolism abnormality of preeclampsia patients is closely related to PPAR gamma-mediated lipid synthesis increase and metabolic regulation imbalance in an anoxic environment, which shows as trophoblast invasion and migration dysfunction, while the PPAR gamma agonist rosiglitazone can relieve trophoblast dysfunction caused by hypoxia. The PPARgamma antagonist T0070907 can aggravate trophoblast dysfunction caused by hypoxia, and the PPARgamma agonist can be used for preparing the medicine for preventing, relieving or treating preeclampsia, so that preeclampsia treatment is realized, and the life quality and the survival rate of patients are further improved.

The present invention provides the use of padsevonil in the preparation of a drug for treating TFE3 rearrangement renal cell carcinoma, and relates to the field of biomedicine technology. The use of padsevonil in the preparation of a drug for treating TFE3 rearrangement renal cell carcinoma. The present invention provides a new drug padsevonil for treating TFE3-RCC, so as to delay the malignant progression of TFE3-RCC and improve the survival of patients. The drug padsevonil provided by the present invention can effectively inhibit the proliferation, invasion and migration of TFE3 rearrangement renal cell carcinoma cells.

The invention relates to an application of miR-6742-5p (micro Ribonucleic Acid-6742-5p) in preparation of an anti-liver cancer product. The nucleotide sequence of the miR-6742-5p is as shown in SEQ ID NO. 1 (sequence identifier number 1). Experiments prove that proliferation, invasion and migration of liver cancer cells can be effectively inhibited by overexpression of miR-6742-5p, malignant progression of tumors can be predicted by detecting the expression level of miR-6742-5p, and therefore the miR-6742-5p has potential application value in the aspect of treatment of malignant tumors such as liver cancer.